Search results
Sarah Cannon Research Institute (SCRI) is a global leader in oncology research, conducting clinical trials in the community for more than 30 years. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country.
A world leader in shaping the standard of care through new cancer drug approvals for 20+ years. Sarah Cannon Research Institute provides community-based access to hundreds of clinical trials a year and has one of the world’s largest early-phase clinical trial menus so ... Discover Sarah Cannon Research Institute.
Our Oncology Research. For the drug development industry, a relationship with Sarah Cannon Research Institute offers: Access to a broad and diverse mix of patients. Experienced, proven investigators and research-focused sites. Efficient, effective clinical trial management services.
Through partnerships with Sarah Cannon Research Institute (SCRI) and other organizations, clinicians have access to enroll patients in groundbreaking oncology clinical trials. Our physicians participate in governance boards and tumor review boards to share best practices and continue learning.
Sarah Cannon Research Institute (SCRI) is a research organization focusing on therapies for patients which include drugs that are in development. With corporate headquarters in Nashville, Tennessee, United States, it conducts community-based clinical trials in oncology, cardiology, gastroenterology, and other therapeutic areas. [1]
Sarah Cannon Research Institute (SCRI) is a world-leading clinical trials facility specialising in the development of new therapies and precision medication for cancer patients. We believe that participation in a clinical trial is the first step in fighting cancer, not the last.
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with...
Choose a hospital or cancer care center with active clinical trials in cancer. Select an oncologist who participates in or leads current clinical trials investigating the latest in cancer treatments.
May 30, 2023 · Sarah Cannon Research Institute (SCRI) believes personalized medicine—tailoring treatment to the individual patient’s cancer—is critical for drug development and offering the right treatment, to the right patient, at the right time.
Learn more about the Sarah Cannon Research Institute leadership team including Chief Executive Officer, Dee Anna Smith.
